SecBot SecBot
SECBOTREPLAY Home › Report › VTRS

VTRS · The District Court of New Jersey adopted a Special Master's…

Viatris Inc · COURT-RULING filed Apr 12, 2026 at 20:00 ET

At the news

MIXEDIMPACT 6/10

COURT-RULING filed Apr 12, 2026 at 20:00 ET

The District Court of New Jersey adopted a Special Master's recommendation to partially grant Teva's motion to dismiss Mylan's antitrust lawsuit regarding Copaxone. Mylan's core Sherman Act claim survives based on allegations of a false 'Dispense as Written' campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit, but claims related to citizen petitions, ANDA litigation, market shift, and copay assistance were dismissed with prejudice. The ruling allows the case to proceed on a narrower set of theories, preserving potential for future damages but reducing the scope of recovery.

  • Court adopted Special Master's R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
  • DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit allegations survive motion to dismiss
  • 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market shift, and copay assistance allegations dismissed with prejudice
  • Foreign allegations struck from complaint

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access